New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

View Resource